MedTrace Logo

VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome

NCT01130246 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 5189

Last updated 2012-10-31

No results posted yet for this study

Summary

The objective of this study is to evaluate the safety and efficacy of short-term A-002 treatment on morbidity and mortality when added to atorvastatin and standard of care in subjects with an acute coronary syndrome (ACS).

Conditions

  • Acute Coronary Syndrome

Interventions

DRUG

A-002, varespladib methyl

A-002 administered once daily in addition to atorvastatin and standard of care

DRUG

Placebo

Placebo administered once daily in addition to atorvastatin and standard of care

Sponsors & Collaborators

  • Anthera Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • United States
  • Australia
  • Canada
  • Czechia
  • Georgia
  • Germany
  • Hungary
  • India
  • Italy
  • Lebanon
  • Netherlands
  • New Zealand
  • Poland
  • Russia
  • South Korea
  • Spain
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01130246 on ClinicalTrials.gov